2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

2080 Isochromosome 17q in myeloid neoplasms: Comparative analysis of genotype and outcomes in the absence (isolated) or presence of other cytogenetic abnormalities

Shraddha Patel, Muhammad Yousuf2, Priyansh Faldu3, Rania Abdelaziz4, Shivani Udyawar5, Merry Nakhleh6, Aysel Bayraktar7, Sudhesh Kumar8, Ali Alsugair9, Kaaren Reichard, MD10, David Viswanatha, MD11, Rong He, MD12, Mithun Shah, MD, PhD13, Devendra Hiwase I, Consultant Haematologist14, Daniel Arber, MD15, Attilio Orazi16, Naseema Gangat, MBBS17, Animesh Pardanani, PhD, MBBS18, Cinthya J. Zepeda Mendoza19, Ayalew Tefferi, MD20
1 Mayo Clinic, Rochester, MN, United States
2 Mayo Clinic, Rochester, MN, United States
3 Mayo Clinic, Rochester, MN, United States
4 Mayo Clinic, Rochester, MN, United States
5 Mayo Clinic, Rochester, MN, United States
6 Mayo Clinic, Rochester, MN, United States
7 Mayo Clinic, Rochester, MN, United States
8 Mayo Clinic, Rochester, MN, United States
9 Mayo Clinic, Rochester, MN, United States
10 Mayo Clinic, Rochester, MN, United States
11 Mayo Clinic, Rochester, MN, United States
12 Mayo Clinic, Rochester, MN, United States
13 Mayo Clinic, Rochester, MN, United States
14 Royal Adelaide Hospital and South Australian Health, Adelaide, Australia
15 University of Chicago, Chicago, United States
16 Texas Tech University, El Paso, United States
17 Mayo Clinic, Rochester, MN, United States
18 Mayo Clinic, Rochester, MN, United States
19 Mayo Clinic, Rochester, MN, United States
20 Mayo Clinic, Rochester, MN, United States

Background:

Isochromosome 17q [i(17) (q10)] is a rare but recurrent structural abnormality in myeloid neoplasms (MNs) characterized by duplication of 17q and concurrent 17p loss. We leveraged the Mayo Clinic cytogenetics repository to conduct a retrospective study of i(17q) in MNs, with the aim of establishing prevalence, cytogenetic context, genotype correlates, corresponding morphologic diagnoses, and impact on overall survival (OS).

Methods:

Pathologic diagnoses were assigned according to the International Consensus Classification (ICC) criteria (Blood 2022. 140:1200). Cytogenetic results were reported according to the International System for Human Cytogenetic Nomenclature (ISCN). 

Results:

A Mayo Clinic enterprise-wide cytogenetic database search (2000–2026) identified abnormalities that included i(17q) in 67 (0.9%) of 7,694 MN cases with abnormal bone marrow (BM) or peripheral blood cytogenetic studies. Study patients (median age 69 years, 71% males; therapy-related 9%) were divided into groups A [isolated i(17q); N=25; 37%], B [i(17q) with one additional karyotypic abnormality; N=24; 36%), and C [i(17q) as a part of complex karyotype [CK]; N=18; 27%). Most frequent co-occurring abnormalities included +8 (22%), and +13 (13%); among the 41 NGS-annotated cases, the most frequent associated mutations included ASXL1 (71%), SRSF2 (51%) and SETBP1 (46%).

 

Specific diagnoses included myelodysplastic syndromes (MDS; N=19; 28%, with [N=7] or without [N=12] excess blasts), acute myeloid leukemia (AML; N=14; 21%), MDS/AML (N=8; 12%), primary myelofibrosis (PMF; N=6; 9%; including 2 patients with accelerated phase), chronic myeloid leukemia (CML; N=4; 6% including 2 with blast phase), chronic eosinophilic leukemia, not otherwise specified (CEL-NOS; N=1; 1.5%), chronic myelomonocytic leukemia (CMML; N=6; 13% including 4 CMML-1 and 2 CMML-2),  and “MDS/MPN, not otherwise specified” (MDS/MPN, NOS; N=9; 22%). Among the latter, 7 (10%) met ICC criteria for “MDS/MPN with isolated i(17q)”.

 

Groups A vs. B. vs. C differed in the frequency of ASXL1 (83% vs. 88% vs. 38% p=<0.01), SETBP1 (75% vs. 46% vs. 23% p=0.03), and NF1 (25% vs 6% vs 0% p=0.07) mutations. The respective groups also showed differences in the frequency of associated +8 (0% vs. 43% vs. 57%; p<0.01) and +13 (0% vs. 75% vs. 25%; p=0.01) abnormalities. TP53 mutations were detected in 7 patients (17%; multi-hit: 3; CK=3). In comparison to group C, group A displayed higher frequencies of ASXL1/SRSF2/SETBP1 (58% vs 8%, p<0.01), ASXL1/SETBP1 (75% vs. 8%, p<0.01), and ASXL1/SRSF2 (58% vs. 15%, p=0.02) mutation signatures.

 

Median OS, calculated from the time of i(17q) detection and censored for allogenic stem cell transplant (ASCT), was similar between groups A, B, and C, at 11, 10, and 19 months, respectively (p=0.25). In contrast, significant survival differences were observed across morphologic diagnoses (p<0.01). Multivariable analysis that included age, CK, i(17q) classification groups, and mutations (including TP53) was conducted and identified advanced age (p<0.01), RUNX1 mutation (p<0.01), and morphologic diagnosis (p<0.01) as independent risk factors for inferior survival.

 

In an age- and CK-adjusted adjusted analysis including morphologic groups with at least 5 informative cases, OS in AML was similar to those of MDS/AML (p=0.3), “MDS/MPN, NOS” (p=0.4), and PMF (p=0.4) but inferior to those of CMML-1/2 and MDS with or without escess blasts (p<0.01 in all instances). Consistently, OS in CMML-1/2 was similar to MDS with (p=0.7) or without (p=0.3) excess blasts but superior to those of MDS/AML (p=0.03), “MDS/MPN, NOS” (p<0.01), and PMF (p=0.03); findings were similar during another OS analysis that replaced “MDS/MPN, NOS” with ICC-defined “MDS/MPN-i(17q)”.

 

In general, OS was significantly better in patients who received ASCT (N=24; 35%) [median 26 vs. 10 months; p<0.01] and in the absence of +13 (median 16 vs. 7 months; p<0.01). Post-ASCT survival (median 19 months) was affected by neither karyotype complexity (p=0.6) nor other associated mutations or clinical variables.

 

Conclusion: i(17q) is rarely encountered in MN (<1% incidence) with about a third of the cases being isolated but with equally dismal prognostic impact. Isolated i(17q) was enriched for ASXL1 and SETBP1 mutations that did not appear to be prognostically relevant. The prognostic impact of i(17q) appeared to be worse in “MDS/MPN, NOS” compared to MDS or CMML. ASCT provides a significant survival benefit.

Shraddha Patel: No relevant conflicts of interest to declare.